WORLD RECORD VIEWS holder on THIS BLOG, ………live, by DR ANTHONY MELVIN CRASTO, Worldpeaceambassador, Worlddrugtracker, Helping millions, 100 million hits on google, pushing boundaries,2.5 lakh plus connections worldwide, 45 lakh plus VIEWS on this blog in 227 countries, 7 CONTINENTS ……A 90 % paralysed man in action for you, I am suffering from transverse mylitis and bound to a wheel chair, [THIS BLOG HOLDS WORLD RECORD VIEWS ]
DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO
FACEBOOK
...................................................................Join me on twitter
..................................................................Join me on google plus
Googleplus
New research presented last week at the Experimental Biology conference in San Diego, California, suggests that regular grape consumption may help alleviate pain associated with symptomatic osteoarthritis of the knee, and improve joint flexibility and overall mobility. Researchers attribute these potential benefits to the polyphenols found in grapes.
The sixteen week clinical study, undertaken by Texas Woman’s University, was designed to investigate the benefits of grape consumption on inflammation and osteoarthritis outcomes. 72 men and women with knee osteoarthritis (OA) were assigned to either consume grapes in the form of a whole grape freeze-dried powder, or a placebo powder.
The study results, presented by lead investigator Shanil Juma, Ph.D., showed that both men and women consuming a grape-enriched diet had a significant decrease in self-reported pain related to activity and an overall decrease in total knee symptoms. This beneficial effect was more pronounced in females. Additionally, age-related differences were observed:…
View original post 374 more words
Rheumatoid arthritis causes chronic pain for almost half of adults by the time they retire, but a new molecular imaging technique can visualize inflammation in the joints, giving doctors a clear read on chronic pain and possible joint destruction, say researchers at the Society of Nuclear Medicine and Molecular Imaging’s 2014 Annual Meeting.
In order to image arthritis inside the joints, researchers used multiple molecular imagingsystems, positron emission tomography (PET) and single photon emission tomography (SPECT), both of which image physiological processes with the help of specialized detectors that pick up signals from injected radionuclide imaging agents. In this case researchers evaluated anti-fibroblast activation protein (FAP) antibodies involved in the inflammation associated with rheumatoid arthritis. This was made possible with radiotracers that combine the molecular compound 28H1, which can bind to FAP in the body, with the radionuclides In-111, used in conjunction with SPECT imaging systems, and Zr-89…
View original post 322 more words
The execs at Dr. Reddy’s Laboratories have taken notice as some of its competitors in India have run afoul of the FDA over loose manufacturing standards. The actions have meant banned plants and plummeting revenues for Ranbaxy Laboratories and Wockhardt. To avoid that fate, Dr. Reddy’s and some other Indian drugmakers have decided it is worth investing hundreds of millions of dollars for new plants and equipment in a country that has traditionally relied on cheap human labor.
Will the FDA finally approve Contrave, Orexigen’s hot new diet drug, this week? Expectations are high for this new weight loss medication, which could prove an important anti-obesity aid. The ruling is expected as soon as tomorrow.
Now temporarily renamed NB32, Contrave was eagerly awaited when it got a startling thumbs-down from the FDA in 2011. The agency demanded additional research into cardiovascular risks.
by
Melanie Haiken
http://www.mmm-online.com/considerations-for-value-preparation-for-asco-2014-drugs/article/354931/
As in previous years, ASCO 2014 did not disappoint, revealing exciting data for promising new treatments, especially in the field of immuno-oncology. Other exciting drugs (CDKs) and newer generations of targeted agents for EGFR and ALK mutations continue to advance treatment of
Considerations for Value Preparation for ASCO 2014 Drugs
Medical Marketing and Media
Other exciting drugs (CDKs) and newer generations of targeted agents for … that are traditionally completed during Phase III of clinical development.
Achillion Kicks Off Phase 1 Trial of Hep C Drug
http://www.dddmag.com/news/2014/06/achillion-kicks-phase-1-trial-hep-c-drug?et_cid=3987909&et_rid=523035093&type=cta
Tue, 06/10/2014
Achillion Pharmaceuticals Inc. announced the company has begun dosing ACH-3422, a uridine-analog nucleotide polymerase inhibitor, for seven days in patients with genotype 1 chronic hepatitis C viral infection (HCV) in its ongoing Phase 1 clinical trial. Proof-of-concept results from this trial are expected to be reported during the fall of 2014. Furthermore, Achillion announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on sovaprevir, an NS3/4A protease inhibitor, to permit the conduct of trials in patients with HCV. Sovaprevir doses of 200 mg once daily, the previously evaluated dose that was well-tolerated with clinical activity in two completed Phase 2 studies, may be used in additional therapeutic clinical trials.
This one snuck past me… and into the clinic. Currently its Ph1 via: WO/2007/132308
this and PF-2341066 both still in the pipeline.
note also WO/2007/138472
Two allosteric inhibitors are better then one!
AZD-6244 is Array’s MEK inhibitor [ARRY-886] which failed a solo ph2 endpoint not too long ago.
MK-2206 is Merck’s ph1 AKT inhibitor
Selinexor (KPT-330)
1393477-72-9
WO2011109799A1
synthesis at http://www.allfordrugs.com/2014/06/10/karyopharm-announces-initiation-of-phase-2-study-of-selinexor-kpt-330/
Karyopharm Announces Initiation of Phase 2 Study of Selinexor (KPT-330) in Patients with …
MarketWatch
“These patients were treated in our Phase 1 clinical trial of Selinexor in … Additional Phase 1 and Phase 2 studies are ongoing or currently planned and … the discovery and development of novel first-in-class drugs directed against …
synthesis
Karyopharm Announces Initiation of Phase 2 Study of Selinexor (KPT-330) an orphan drug
THANKS AND REGARD’S
DR ANTHONY MELVIN CRASTO Ph.D
amcrasto@gmail.com
VIETNAM
http://me.zing.vn/u/amcrasto
ICELAND
http://amcrasto.bland.is/
RUSSIA
http://www.100zakladok.ru/amcrasto/
http://bobrdobr.ru/people/amcrasto/
New Drug Approvals 